Identification

Name
Quinapril
Accession Number
DB00881  (APRD00523)
Type
Small Molecule
Groups
Approved, Investigational
Description

Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Quinapril may be used to treat essential hypertension and congestive heart failure.

Structure
Thumb
Synonyms
  • Quinaprilum
External IDs
C09AA06
Product Ingredients
IngredientUNIICASInChI Key
Quinapril Hydrochloride33067B3N2M82586-55-8IBBLRJGOOANPTQ-JKVLGAQCSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AccuprilTablet, film coated10 mg/1OralCardinal Health1991-11-19Not applicableUs
AccuprilTablet, film coated10 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated20 mg/1OralCardinal Health1991-11-19Not applicableUs
AccuprilTablet, film coated20 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated5 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
AccuprilTablet, film coated40 mg/1Oralbryant ranch prepack1991-11-19Not applicableUs
AccuprilTablet, film coated40 mg/1OralParke Davis Div Of Pfizer Inc1991-11-19Not applicableUs
Accupril 5mg TabTablet5 mgOralPfizer1992-12-31Not applicableCanada
Accupril Tab 10mgTablet10 mgOralPfizer1992-12-31Not applicableCanada
Accupril Tab 20mgTablet20 mgOralPfizer1992-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quinaprilTablet10 mgOralApotex Corporation2013-07-02Not applicableCanada
Apo-quinaprilTablet5 mgOralApotex Corporation2013-07-02Not applicableCanada
Apo-quinaprilTablet20 mgOralApotex Corporation2013-07-02Not applicableCanada
Apo-quinaprilTablet40 mgOralApotex Corporation2013-07-02Not applicableCanada
QuinaprilTablet5 mg/1OralAv Pak2014-08-052016-03-11Us
QuinaprilTablet, film coated40 mg/1OralA S Medication Solutions2013-04-292017-06-20Us65862 0620 90 nlmimage10 9e4b4f5a
QuinaprilTablet, film coated20 mg/1OralAurobindo Pharma2013-04-29Not applicableUs
QuinaprilTablet, film coated20 mg/1OralNucare Pharmaceuticals, Inc.2013-04-29Not applicableUs
QuinaprilTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2005-03-03Not applicableUs
QuinaprilTablet, film coated40 mg/1OralSun Pharmaceutical Industries Limited2009-06-18Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
QuinaprilTablet5 1/1OralSolco healthcare U.S., LLC2017-11-10Not applicableUs
QuinaprilTablet40 mg/1OralSolco healthcare U.S., LLC2016-03-16Not applicableUs
QuinaprilTablet10 mg/1OralSolco healthcare U.S., LLC2017-11-10Not applicableUs
QuinaprilTablet20 mg/1OralSolco healthcare U.S., LLC2017-11-10Not applicableUs
International/Other Brands
Accuprin (Pfizer (Italy)) / Accupro (Pfizer (Austria, Denmark, Finland, Germany, Hungary, Ireland, Sweden, Switzerland, United Kingdom, Ukraine), Godecke (Czech Republic, Germany, Poland, Russia), Parke, Davis (Germany)) / Acequin / Acuitel / Korec / Quinazil
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AccureticQuinapril Hydrochloride (20 mg/1) + Hydrochlorothiazide (25 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
AccureticQuinapril Hydrochloride (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
AccureticQuinapril Hydrochloride (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralParke Davis Div Of Pfizer Inc1999-12-28Not applicableUs
Accuretic 10/12.5 mgQuinapril (10 mg) + Hydrochlorothiazide (12.5 mg)TabletOralPfizer1998-10-01Not applicableCanada
Accuretic 20/12.5 mgQuinapril (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralPfizer1998-10-01Not applicableCanada
Accuretic 20/25 mgQuinapril (20 mg) + Hydrochlorothiazide (25 mg)TabletOralPfizer2003-06-02Not applicableCanada
Apo-quinapril/hctzQuinapril (10 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2013-08-13Not applicableCanada
Apo-quinapril/hctzQuinapril (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2013-08-13Not applicableCanada
Apo-quinapril/hctzQuinapril (20 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2013-08-13Not applicableCanada
Gd-quinapril HctzQuinapril (20 mg) + Hydrochlorothiazide (25 mg)TabletOralGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Categories
UNII
RJ84Y44811
CAS number
85441-61-8
Weight
Average: 438.5161
Monoisotopic: 438.21547208
Chemical Formula
C25H30N2O5
InChI Key
JSDRRTOADPPCHY-HSQYWUDLSA-N
InChI
InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]@H](C)C(=O)N1CC2=CC=CC=C2C[[email protected]]1C(O)=O

Pharmacology

Indication

For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structured Indications
Pharmacodynamics

Quinapril is a nonpeptide, non-sulfhydryl prodrug that is deesterified to quinaprilat (quinapril diacid), its major active metabolite following oral administration. Quinaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of quinaprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Quinaprilat, the principle active metabolite of quinapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Quinaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Peak plasma concentrations of quinapril occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.

Volume of distribution
Not Available
Protein binding

97%

Metabolism

Hepatic.

Route of elimination

Quinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose

Half life

Elimination half life is 2 hours with a prolonged terminal phase of 25 hours.

Clearance
Not Available
Toxicity

Overdose may lead to severe hypotension. LD50=1739mg/kg (orally in mice). The most common adverse effects observed in controlled clinical trials were dizziness, cough, chest pain, dyspnea, fatigue, and nausea/vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Quinapril Metabolism PathwayDrug metabolism
Quinapril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Quinapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Quinapril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Quinapril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Quinapril is combined with Acemetacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Quinapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Quinapril is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Quinapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Quinapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Quinapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Quinapril.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Quinapril.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Quinapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Quinapril.Approved, Withdrawn
AmbrisentanQuinapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Quinapril.Experimental, Investigational
AmifostineQuinapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Quinapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Quinapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Quinapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Quinapril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Quinapril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Quinapril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quinapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Quinapril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Quinapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Quinapril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Quinapril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Quinapril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Quinapril is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Quinapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Quinapril is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Quinapril is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Quinapril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Quinapril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Quinapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Quinapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Quinapril.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Quinapril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Quinapril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Quinapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Quinapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Azapropazone.Withdrawn
AzathioprineQuinapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Quinapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Quinapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Quinapril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Quinapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Quinapril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Quinapril.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Quinapril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Quinapril is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quinapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Quinapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Quinapril is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Quinapril is combined with Benzydamine.Approved
BepridilQuinapril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Quinapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Quinapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Quinapril is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Quinapril.Experimental
BimatoprostQuinapril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quinapril.Approved
BoceprevirThe serum concentration of Quinapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Quinapril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Quinapril.Approved, Investigational
BQ-123Quinapril may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Quinapril is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Quinapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Quinapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quinapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Quinapril is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Quinapril is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Quinapril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quinapril.Approved, Investigational
BupranololQuinapril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Quinapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Quinapril.Experimental
CafedrineQuinapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Quinapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Quinapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Quinapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Quinapril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Captopril.Approved
CarbamazepineThe metabolism of Quinapril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Quinapril.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Quinapril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Quinapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Quinapril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Quinapril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Quinapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Celecoxib.Approved, Investigational
CeliprololQuinapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Quinapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quinapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Quinapril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quinapril.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Quinapril.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quinapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Quinapril is combined with Choline magnesium trisalicylate.Approved
CicletanineQuinapril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Quinapril.Approved, Investigational
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Quinapril.Approved, Investigational, Withdrawn
CiprofloxacinQuinapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Quinapril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Quinapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Quinapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Quinapril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quinapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Quinapril is combined with Clonixin.Approved
CloranololQuinapril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Quinapril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Quinapril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Quinapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Quinapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Quinapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Quinapril.Approved
CyclopenthiazideQuinapril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Quinapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Quinapril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Quinapril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Quinapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Quinapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Quinapril.Approved, Investigational
DelaprilQuinapril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Quinapril.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Quinapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Quinapril.Investigational
DeserpidineQuinapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Quinapril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Quinapril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quinapril.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Quinapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Quinapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Quinapril.Approved, Investigational
diethylnorspermineQuinapril may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Quinapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Quinapril is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Quinapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Quinapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Quinapril.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Quinapril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Quinapril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Quinapril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Quinapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Quinapril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quinapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Quinapril.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Quinapril.Approved, Investigational, Vet Approved
DrospirenoneQuinapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Droxicam.Approved
DuloxetineQuinapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Quinapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Quinapril.Approved
E-6201The risk or severity of adverse effects can be increased when Quinapril is combined with E-6201.Investigational
EfonidipineQuinapril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Quinapril.Approved, Vet Approved
EnalaprilatQuinapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Quinapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Quinapril.Approved, Investigational
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Quinapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Quinapril.Approved
EpanololQuinapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Quinapril.Approved
EpoprostenolQuinapril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quinapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Quinapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Quinapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Quinapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Quinapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Quinapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Quinapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Quinapril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Quinapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Quinapril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Quinapril is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Quinapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Quinapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Quinapril is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Quinapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Quinapril is combined with Evening primrose oil.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Quinapril is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Quinapril is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Quinapril is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Quinapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Quinapril is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Feprazone.Experimental
Ferulic acidQuinapril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Quinapril.Approved, Investigational
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Quinapril.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Quinapril is combined with Floctafenine.Approved, Withdrawn
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Quinapril.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Quinapril is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Quinapril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quinapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Quinapril.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Quinapril.Approved, Vet Approved
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Quinapril.Investigational
GarlicThe serum concentration of Quinapril can be decreased when it is combined with Garlic.Approved
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Quinapril.Investigational, Withdrawn
GuacetisalGuacetisal may decrease the antihypertensive activities of Quinapril.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Quinapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Quinapril.Approved
GuanazodineQuinapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineQuinapril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Quinapril is combined with Guanfacine.Approved, Investigational
GuanoclorQuinapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzQuinapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanQuinapril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Quinapril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Quinapril.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Quinapril.Experimental
HeparinHeparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
HexamethoniumQuinapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Quinapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Quinapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Quinapril is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Quinapril.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Quinapril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Quinapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Quinapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Quinapril.Approved
IloprostIloprost may increase the hypotensive activities of Quinapril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Quinapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Quinapril is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Quinapril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Quinapril.Approved
IndenololQuinapril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Quinapril is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Quinapril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Quinapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Quinapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Quinapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Quinapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quinapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Quinapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Quinapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Quinapril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Quinapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Quinapril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Quinapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Quinapril.Approved
LacidipineQuinapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Quinapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Quinapril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Quinapril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Quinapril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Quinapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Quinapril.Approved, Investigational
LevodopaQuinapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Quinapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Quinapril.Approved
LinsidomineQuinapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quinapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Quinapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Quinapril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Quinapril.Experimental
LofexidineQuinapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Quinapril is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Quinapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Quinapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Lumiracoxib.Approved, Investigational
MacitentanQuinapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Quinapril is combined with Magnesium salicylate.Approved
ManidipineQuinapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Quinapril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Quinapril is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Quinapril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinapril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Quinapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Quinapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Quinapril is combined with Metamizole.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Quinapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Quinapril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Quinapril.Approved
MethoserpidineQuinapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quinapril.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Quinapril.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Quinapril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Quinapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Quinapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Quinapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Quinapril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Quinapril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Quinapril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Quinapril.Approved, Investigational
MetyrosineQuinapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilQuinapril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Quinapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Quinapril.Approved
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Quinapril.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Quinapril.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Quinapril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Quinapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Quinapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Quinapril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Quinapril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Quinapril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Quinapril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Quinapril.Approved, Investigational
MuzolimineQuinapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Quinapril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Quinapril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Quinapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Quinapril is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Quinapril is combined with Naftifine.Approved
NaftopidilQuinapril may increase the hypotensive activities of Naftopidil.Investigational
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Quinapril.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Quinapril is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Quinapril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Quinapril.Approved, Withdrawn
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Quinapril.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Quinapril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Quinapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Quinapril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Quinapril.Approved
NicorandilNicorandil may increase the hypotensive activities of Quinapril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Quinapril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Quinapril is combined with Niflumic Acid.Approved
NiguldipineQuinapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineQuinapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Quinapril is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quinapril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quinapril.Approved
NitrendipineQuinapril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Quinapril.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Quinapril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quinapril.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quinapril.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Quinapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Quinapril.Approved
ObinutuzumabQuinapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Quinapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quinapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Quinapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Olsalazine.Approved
OmapatrilatQuinapril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Quinapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Quinapril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxaprozin.Approved
Oxolinic acidThe serum concentration of Oxolinic acid can be decreased when it is combined with Quinapril.Experimental
OxprenololQuinapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quinapril.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Quinapril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Quinapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Quinapril is combined with Parthenolide.Investigational
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Quinapril.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Quinapril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Quinapril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Quinapril.Approved, Vet Approved
PentoliniumQuinapril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Quinapril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Quinapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Quinapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Quinapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Quinapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Quinapril.Approved
PhenoxybenzamineQuinapril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Quinapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Quinapril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Quinapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Quinapril.Approved
PinacidilPinacidil may increase the hypotensive activities of Quinapril.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Quinapril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Quinapril.Approved, Investigational
Pipemidic acidThe serum concentration of Pipemidic acid can be decreased when it is combined with Quinapril.Experimental
PiretanidePiretanide may increase the hypotensive activities of Quinapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Quinapril.Approved
Piromidic acidThe serum concentration of Piromidic acid can be decreased when it is combined with Quinapril.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Quinapril.Withdrawn
Platelet Activating FactorQuinapril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideQuinapril may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Quinapril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Quinapril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Quinapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Quinapril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Quinapril.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Quinapril is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Quinapril is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Quinapril.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Quinapril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Quinapril.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Quinapril.Investigational
PTC299The risk or severity of adverse effects can be increased when Quinapril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quinapril is combined with Quetiapine.Approved
QuinethazoneQuinethazone may increase the hypotensive activities of Quinapril.Approved
QuinineQuinine may increase the hypotensive activities of Quinapril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Quinapril.Approved
RasagilineRasagiline may increase the hypotensive activities of Quinapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Quinapril.Approved
RescinnamineQuinapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quinapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Quinapril is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Quinapril.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Quinapril.Approved
RisperidoneQuinapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabQuinapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Quinapril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Quinapril.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Quinapril.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Quinapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Quinapril.Approved
RufloxacinThe serum concentration of Rufloxacin can be decreased when it is combined with Quinapril.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Quinapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Quinapril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Quinapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Quinapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Quinapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Quinapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Quinapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Quinapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Quinapril.Approved, Investigational, Vet Approved
SelexipagQuinapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Quinapril is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Quinapril is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Quinapril is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Quinapril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Quinapril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Quinapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Quinapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Quinapril.Approved, Investigational
SitafloxacinThe serum concentration of Sitafloxacin can be decreased when it is combined with Quinapril.Experimental, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Quinapril.Approved, Investigational
SitaxentanQuinapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Quinapril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Quinapril.Approved
Sodium phosphateQuinapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Quinapril.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
SpiraprilQuinapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quinapril.Approved
SRT501The risk or severity of adverse effects can be increased when Quinapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Quinapril can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Quinapril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinapril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Quinapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Quinapril is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Quinapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Quinapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Quinapril.Approved, Investigational
TalinololQuinapril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Quinapril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Quinapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quinapril.Approved, Investigational
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Quinapril.Withdrawn
TemocaprilQuinapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Quinapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Quinapril is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Quinapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Quinapril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Quinapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Quinapril is combined with Teriflunomide.Approved
TerlipressinQuinapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineQuinapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Quinapril.Approved, Investigational, Withdrawn
TheodrenalineQuinapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Quinapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Quinapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Quinapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Quinapril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Quinapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Quinapril is combined with Tiaprofenic acid.Approved
TiboloneQuinapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenQuinapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Quinapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Quinapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Quinapril.Approved
TipranavirThe serum concentration of Quinapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Quinapril.Approved
TolazolineTolazoline may increase the hypotensive activities of Quinapril.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Quinapril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolmetin.Approved
TolonidineQuinapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Quinapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Quinapril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Quinapril.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quinapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Quinapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Quinapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Quinapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Quinapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Quinapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Quinapril.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Quinapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Quinapril.Approved
TribenosideThe risk or severity of adverse effects can be increased when Quinapril is combined with Tribenoside.Experimental
TrichlormethiazideQuinapril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Quinapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Quinapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Quinapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Quinapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Quinapril is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Quinapril.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Quinapril.Approved, Investigational, Withdrawn
UdenafilUdenafil may increase the antihypertensive activities of Quinapril.Approved, Investigational
UnoprostoneQuinapril may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Quinapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Quinapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Quinapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Quinapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Quinapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Quinapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Quinapril.Approved, Investigational
VincamineQuinapril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineQuinapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideQuinapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineQuinapril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Quinapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Quinapril is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Quinapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Quinapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilQuinapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Quinapril is combined with Zomepirac.Withdrawn
Food Interactions
  • Do not take with a high-fat meal.
  • Herbs that may attenuate the antihypertensive effect of quinapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of quinapril.
  • Quinapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.

References

Synthesis Reference

Om P. Goel, Uldis Krolls, "Crystalline quinapril and a process for producing the same." U.S. Patent US4761479, issued August, 1982.

US4761479
General References
  1. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care. 2004 Jul;27(7):1712-5. [PubMed:15220251]
  2. Kieback AG, Felix SB, Reffelmann T: Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. [PubMed:19761414]
  3. Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS: The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001 May 1;87(9):1058-63. [PubMed:11348602]
  4. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol. 2004 Feb;44(2):150-7. [PubMed:14747423]
  5. Valles Prats M, Matas Serra M, Bronsoms Artero J, Mate Benito G, Torguet Escuder P, Mauri Nicolas JM: Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int Suppl. 1996 Jun;55:S104-6. [PubMed:8743525]
  6. Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH: Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):130-4. [PubMed:15526248]
  7. Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T: Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull. 2003 Jun;26(6):872-5. [PubMed:12808303]
External Links
Human Metabolome Database
HMDB15019
KEGG Drug
D03752
KEGG Compound
C07398
PubChem Compound
54892
PubChem Substance
46506309
ChemSpider
49565
BindingDB
50368166
ChEBI
8713
ChEMBL
CHEMBL1592
Therapeutic Targets Database
DAP000588
PharmGKB
PA451205
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Quinapril
ATC Codes
C09AA06 — QuinaprilC09BA06 — Quinapril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers4
3CompletedPreventionDiabetes, Diabetes Mellitus Type 11
4CompletedNot AvailableCABGs1
4CompletedNot AvailableDiabetic Autonomic Neuropathy1
4CompletedPreventionHypertensive1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedTreatmentHypertensive3
4CompletedTreatmentHypertensive / Menopause1
4CompletedTreatmentIschaemic Heart Diseases1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4TerminatedTreatmentHypertensive1
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedTreatmentDiabetes / Hypertensive1

Pharmacoeconomics

Manufacturers
  • Pfizer pharmaceuticals ltd
  • Actavis totowa llc
  • Apotex inc
  • Genpharm inc
  • Invagen pharmaceuticals inc
  • Lupin ltd
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
TabletOral10 mg
TabletOral20 mg
TabletOral40 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
TabletOral5 1/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
TabletOral
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Accupril 10 mg tablet2.02USD tablet
Accupril 20 mg tablet2.02USD tablet
Accupril 40 mg tablet2.02USD tablet
Accupril 5 mg tablet2.02USD tablet
Quinapril 10 mg tablet1.57USD tablet
Quinapril 20 mg tablet1.57USD tablet
Quinapril 40 mg tablet1.57USD tablet
Quinapril 5 mg tablet1.57USD tablet
Quinapril HCl 10 mg tablet1.27USD tablet
Quinapril HCl 20 mg tablet1.27USD tablet
Quinapril HCl 40 mg tablet1.27USD tablet
Quinapril HCl 5 mg tablet1.27USD tablet
Quinaretic 10-12.5 mg tablet1.27USD tablet
Quinaretic 20-12.5 mg tablet1.27USD tablet
Quinaretic 20-25 mg tablet1.27USD tablet
Accupril 10 mg Tablet0.96USD tablet
Accupril 20 mg Tablet0.96USD tablet
Accupril 40 mg Tablet0.96USD tablet
Accupril 5 mg Tablet0.96USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5684016No1995-05-042015-05-04Us
CA2023089No2003-01-142010-08-10Canada
CA1331615No1994-08-232011-08-23Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)120-130 °CNot Available
water solubility1 mg/LNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0085 mg/mLALOGPS
logP1.39ALOGPS
logP1.96ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.7ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity119.96 m3·mol-1ChemAxon
Polarizability47.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5597
Blood Brain Barrier-0.9409
Caco-2 permeable-0.8208
P-glycoprotein substrateSubstrate0.8895
P-glycoprotein inhibitor IInhibitor0.7344
P-glycoprotein inhibitor IIInhibitor0.5869
Renal organic cation transporterNon-inhibitor0.8258
CYP450 2C9 substrateNon-substrate0.8594
CYP450 2D6 substrateNon-substrate0.8412
CYP450 3A4 substrateSubstrate0.5356
CYP450 1A2 substrateNon-inhibitor0.8597
CYP450 2C9 inhibitorNon-inhibitor0.6832
CYP450 2D6 inhibitorNon-inhibitor0.8636
CYP450 2C19 inhibitorNon-inhibitor0.6016
CYP450 3A4 inhibitorInhibitor0.5347
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5162
Ames testNon AMES toxic0.9091
CarcinogenicityNon-carcinogens0.9294
BiodegradationNot ready biodegradable0.9596
Rat acute toxicity2.2690 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9763
hERG inhibition (predictor II)Inhibitor0.7176
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Tetrahydroisoquinolines / Fatty acid esters / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Amino acids
show 8 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / Tetrahydroisoquinoline / Fatty acid ester / Aralkylamine / Monocyclic benzene moiety / Dicarboxylic acid or derivatives
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dicarboxylic acid monoester, ethyl ester, isoquinolines (CHEBI:8713)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Culy CR, Jarvis B: Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 2002;62(2):339-85. [PubMed:11817979]
  3. Klutchko S, Blankley CJ, Fleming RW, Hinkley JM, Werner AE, Nordin I, Holmes A, Hoefle ML, Cohen DM, Essenburg AD, et al.: Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. J Med Chem. 1986 Oct;29(10):1953-61. [PubMed:3020249]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34